BioSpace News Archive

Aravive, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s lead program, batiraxcept, for treatment of patients with advanced or metastatic clear cell renal cell carcinoma.

Femasys Inc. today announced that it has completed over 25% of its targeted enrollment (214 patient fertility cycles) in its FemaSeed ® de novo trial.

PolyPid Ltd. today announced that Phase 2 clinical data for D-PLEX 100 will be highlighted in a podium presentation at the first triennial International Orthopaedic Trauma Association meeting being held on December 14-16, 2022, at the RAI Amsterdam Exhibition and Conference Center in Amsterdam, The Netherlands.

atai Life Sciences N.V. announced today its appointment of Dr. Kirpekar to serve as the Company’s Chief Business Officer, effective today.

BiondVax announced today statistically significant (p<0.001) efficacy results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (NanoAb) COVID-19 therapy.

Can people living with dementia still make personal choices, have meaningful relationships, continue to be valued and even develop novel interests and abilities? The answer is yes, when their support is based on the revolutionary Possibilities by Baycrest™ model.

Milestone Pharmaceuticals Inc. today announced that members of the Company’s management team will host a virtual commercial deep-dive event on Tuesday, December 6, 2022 at 1:00 p.m. ET.

Tyra Biosciences, Inc. today announced the initiation of its SURF301 Phase 1/2 clinical study, with first patient dosed with TYRA-300.

Glioblastoma multiforme (GBM), the most common type of brain cancer, is notoriously difficult to treat. Its tumor cells mutate rapidly, pushing into deep areas of the brain that can be difficult to reach with surgery and other treatments.

Compugen Ltd. announced today that Anat Cohen-Dayag , Ph.D., President and CEO, and additional members of its management team will participate in a virtual fireside chat at the upcoming JMP Securities Hematology and Oncology Summit. The fireside chat will take place on Tuesday, December 6, 2022, at 10:20 am ET.